SeqLL Inc
OTC:ATLN

Watchlist Manager
SeqLL Inc Logo
SeqLL Inc
OTC:ATLN
Watchlist
Price: 1.9 USD -6.86% Market Closed
Market Cap: 111.2m USD

SeqLL Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

SeqLL Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
SeqLL Inc
OTC:ATLN
Cash from Operating Activities
$3.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Operating Activities
$7.7B
CAGR 3-Years
-2%
CAGR 5-Years
2%
CAGR 10-Years
12%
Danaher Corp
NYSE:DHR
Cash from Operating Activities
$6.3B
CAGR 3-Years
-9%
CAGR 5-Years
4%
CAGR 10-Years
5%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Operating Activities
$996.4m
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Cash from Operating Activities
$1.5B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
1%
IQVIA Holdings Inc
NYSE:IQV
Cash from Operating Activities
$2.8B
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
18%
No Stocks Found

SeqLL Inc
Glance View

SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. The company is headquartered in Woburn, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-08-27. The company offers ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing solutions. The company uses its true single molecule sequencing (tSMS) technology. SeqLL offers RNA and specialty DNA sequencing services utilizing tSMS. SeqLL offers a range of RNA sequencing services, including its direct RNA sequencing without conversion to complementary DNA (cDNA). The firm operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Its testing services are fully customizable to customers research needs and challenges. Its SeqLL technology is used for various application, such as life sciences research and development, liquid biopsy, clinical diagnostics and microbiome analysis. The tSMS platform offers a sample preparation process.

ATLN Intrinsic Value
7.53 USD
Undervaluation 75%
Intrinsic Value
Price

See Also

What is SeqLL Inc's Cash from Operating Activities?
Cash from Operating Activities
3.4m USD

Based on the financial report for Sep 30, 2025, SeqLL Inc's Cash from Operating Activities amounts to 3.4m USD.

Back to Top